Evidence map›Paper›PMID 32658897›Full record

ArticlePloS one2020

The chromatin-remodeling enzyme CHD3 plays a role in embryonic viability but is dispensable for early vascular development.

Jun Xie, Siqi Gao, Christopher Schafer, Sarah Colijn, Vijay Muthukumar, Courtney T Griffin

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jun XieCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, United States of America.
Siqi GaoCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, United States of America.
Christopher SchaferCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, United States of America.
Sarah ColijnCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, United States of America.
Vijay MuthukumarCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, United States of America.
Courtney T GriffinCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, United States of America.ORCID 0000-0001-8100-3171
Oklahoma Medical Research Foundation · US

Funding

Pilot ProjectP30GM114731 · NIGMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI MCEVER, RODGER PAUL · 2016 to 2020
$6.5M
Protease-Mediated Vascular Instability in Development and DiseaseR35HL144605 · NHLBI · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI GRIFFIN, COURTNEY T · 2019 to 2025
$5.9M
NHLBI NIH HHS R35 HL144605NIGMS NIH HHS P30 GM114731
6 · The paper itself

Abstract

ATP-dependent chromatin-remodeling complexes epigenetically modulate transcription of target genes to impact a variety of developmental processes. Our lab previously demonstrated that CHD4-a central ATPase and catalytic enzyme of the NuRD chromatin-remodeling complex-plays an important role in murine embryonic endothelial cells by transcriptionally regulating vascular integrity at midgestation. Since NuRD complexes can incorporate the ATPase CHD3 as an alternative to CHD4, we questioned whether the CHD3 enzyme likewise modulates vascular development or integrity. We generated a floxed allele of Chd3 but saw no evidence of lethality or vascular anomalies when we deleted it in embryonic endothelial cells in vivo (Chd3ECKO). Furthermore, double-deletion of Chd3 and Chd4 in embryonic endothelial cells (Chd3/4ECKO) did not dramatically alter the timing and severity of embryonic phenotypes seen in Chd4ECKO mutants, indicating that CHD3 does not play a cooperative role with CHD4 in early vascular development. However, excision of Chd3 at the epiblast stage of development with a Sox2-Cre line allowed us to generate global heterozygous Chd3 mice (Chd3Δ/+), which were subsequently intercrossed and revealed partial lethality of Chd3Δ/Δ mutants prior to weaning. Tissues from surviving Chd3Δ/Δ mutants helped us confirm that CHD3 was efficiently deleted in these animals and that CHD3 is highly expressed in the gonads and brains of adult wildtype mice. Therefore, Chd3-flox mice will be beneficial for future studies about roles for this chromatin-remodeling enzyme in viable embryonic development and in gonadal and brain physiology.

Indexed as

AnimalsBlood VesselsChromatin Assembly and DisassemblyDNA-Binding ProteinsEmbryo LossEmbryo, MammalianFemaleGene DeletionGene Expression Regulation, DevelopmentalMaleMiceChd7 protein, mouseDNA-Binding Proteins

Identifiers

PMID32658897
PMCPMC7357745
OpenAlexW3043745326

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.